1. Academic Validation
  2. The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition

The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition

  • ChemMedChem. 2022 Oct 6;17(19):e202200303. doi: 10.1002/cmdc.202200303.
Pascal Furet 1 Vincent Bordas 1 Mickaël Le Douget 1 Bahaa Salem 1 Yannick Mesrouze 2 Patricia Imbach-Weese 1 Holger Sellner 1 Markus Voegtle 1 Nicolas Soldermann 1 Emilie Chapeau 2 Markus Wartmann 2 Clemens Scheufler 3 Cesar Fernandez 3 Joerg Kallen 3 Vito Guagnano 1 Patrick Chène 2 Tobias Schmelzle 2
Affiliations

Affiliations

  • 1 Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.
  • 2 Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.
  • 3 Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.
Abstract

Inhibition of the YAP-TEAD protein-protein interaction is an attractive therapeutic concept under intense investigation with the objective to treat cancers associated with a dysregulation of the Hippo pathway. However, owing to the very extended surface of interaction of the two proteins, the identification of small drug-like molecules able to efficiently prevent YAP from binding to TEAD by direct competition has been elusive so far. We disclose here the discovery of the first class of small molecules potently inhibiting the YAP-TEAD interaction by binding at one of the main interaction sites of YAP at the surface of TEAD. These inhibitors, providing a path forward to pharmacological intervention in the Hippo pathway, evolved from a weakly active virtual screening hit advanced to high potency by structure-based design.

Keywords

PPI inhibitors •virtual screening; TEAD; YAP; structure-based design.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-151525
    98.99%, YAP-TEAD PPI Inhibitor
    YAP